-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Dyne Therapeutics (NASDAQ:DYN) Trading 4.6% Higher on Analyst Upgrade
Dyne Therapeutics (NASDAQ:DYN) Trading 4.6% Higher on Analyst Upgrade
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) shares traded up 4.6% on Wednesday after Piper Sandler raised their price target on the stock from $17.00 to $23.00. The stock traded as high as $12.21 and last traded at $12.21. 100 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 226,386 shares. The stock had previously closed at $11.67.
Several other research firms also recently weighed in on DYN. Raymond James assumed coverage on shares of Dyne Therapeutics in a research report on Monday, July 11th. They issued an "outperform" rating and a $15.00 target price for the company. Chardan Capital assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, July 20th. They set a "buy" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.00.
Get Dyne Therapeutics alerts:Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. Deep Track Capital LP acquired a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $27,255,000. Franklin Resources Inc. lifted its stake in shares of Dyne Therapeutics by 48.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,746,481 shares of the company's stock worth $11,999,000 after acquiring an additional 568,533 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Dyne Therapeutics by 51.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,254,800 shares of the company's stock worth $14,920,000 after acquiring an additional 427,800 shares during the period. Woodline Partners LP lifted its stake in shares of Dyne Therapeutics by 58.0% in the 1st quarter. Woodline Partners LP now owns 813,139 shares of the company's stock worth $7,839,000 after acquiring an additional 298,538 shares during the period. Finally, Monashee Investment Management LLC lifted its stake in Dyne Therapeutics by 193.5% during the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock valued at $2,696,000 after purchasing an additional 184,404 shares during the last quarter. 90.22% of the stock is owned by institutional investors and hedge funds.
Dyne Therapeutics Stock Up 18.3 %
The firm has a market capitalization of $714.36 million, a price-to-earnings ratio of -3.91 and a beta of 0.70. The firm's 50 day moving average is $11.17 and its 200 day moving average is $8.25.Dyne Therapeutics (NASDAQ:DYN – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.22). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current year.
About Dyne Therapeutics
(Get Rating)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Stories
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Rating) shares traded up 4.6% on Wednesday after Piper Sandler raised their price target on the stock from $17.00 to $23.00. The stock traded as high as $12.21 and last traded at $12.21. 100 shares traded hands during mid-day trading, a decline of 100% from the average session volume of 226,386 shares. The stock had previously closed at $11.67.
戴恩治疗公司(纳斯达克代码:DYN-GET评级)股价周三上涨4.6%,此前派珀·桑德勒将该股目标价从17.00美元上调至23.00美元。该股盘中一度涨至12.21美元,最新报12.21美元。午盘成交量为100股,较226,386股的日均成交量下降100%。该股此前收盘价为11.67美元。
Several other research firms also recently weighed in on DYN. Raymond James assumed coverage on shares of Dyne Therapeutics in a research report on Monday, July 11th. They issued an "outperform" rating and a $15.00 target price for the company. Chardan Capital assumed coverage on shares of Dyne Therapeutics in a research report on Wednesday, July 20th. They set a "buy" rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $21.00.
其他几家研究公司最近也加入了对Dyn的看法。雷蒙德·詹姆斯在7月11日星期一的一份研究报告中对戴恩治疗公司的股票进行了报道。他们对该公司的评级为“跑赢大盘”,目标价为15.00美元。查丹资本在7月20日星期三的一份研究报告中承担了对戴恩治疗公司股票的报道。他们为该公司设定了“买入”评级和17.00美元的目标价。一名分析师对该股的评级为卖出,四名分析师对该公司股票的评级为买入。根据MarketBeat的数据,该公司目前的平均评级为“中等买入”,平均目标价为21.00美元。
Institutional Inflows and Outflows
机构资金流入和流出
A number of hedge funds and other institutional investors have recently bought and sold shares of DYN. Deep Track Capital LP acquired a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $27,255,000. Franklin Resources Inc. lifted its stake in shares of Dyne Therapeutics by 48.3% in the 2nd quarter. Franklin Resources Inc. now owns 1,746,481 shares of the company's stock worth $11,999,000 after acquiring an additional 568,533 shares during the period. Point72 Asset Management L.P. lifted its stake in shares of Dyne Therapeutics by 51.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,254,800 shares of the company's stock worth $14,920,000 after acquiring an additional 427,800 shares during the period. Woodline Partners LP lifted its stake in shares of Dyne Therapeutics by 58.0% in the 1st quarter. Woodline Partners LP now owns 813,139 shares of the company's stock worth $7,839,000 after acquiring an additional 298,538 shares during the period. Finally, Monashee Investment Management LLC lifted its stake in Dyne Therapeutics by 193.5% during the first quarter. Monashee Investment Management LLC now owns 279,704 shares of the company's stock valued at $2,696,000 after purchasing an additional 184,404 shares during the last quarter. 90.22% of the stock is owned by institutional investors and hedge funds.
一些对冲基金和其他机构投资者最近买卖了Dyn的股票。Deep Track Capital LP在第四季度收购了戴恩治疗公司的新股份,价值约27,255,000美元。富兰克林资源公司(Franklin Resources Inc.)在第二季度增持了戴恩治疗公司48.3%的股份。富兰克林资源公司在此期间增持了568,533股,目前持有1,746,481股该公司股票,价值11,999,000美元。Point72 Asset Management L.P.在第四季度增持了Dye Treateutics的股份51.7%。Point72 Asset Management L.P.在此期间额外收购了427,800股,现在拥有1,254,800股该公司股票,价值14,920,000美元。Woodline Partners LP在第一季度增持了Dye Treateutics 58.0%的股份。在此期间增持了298,538股后,Woodline Partners LP现在拥有813,139股该公司的股票,价值7,839,000美元。最后,Monashee Investment Management LLC在第一季度将其在戴恩治疗公司的股份增加了193.5%。Monashee Investment Management LLC在上个季度额外购买了184,404股后,现在拥有279,704股该公司股票,价值2,696,000美元。90.22%的股票由机构投资者和对冲基金持有。
Dyne Therapeutics Stock Up 18.3 %
戴恩治疗公司股票上涨18.3%
Dyne Therapeutics (NASDAQ:DYN – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.79) by ($0.22). On average, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.59 earnings per share for the current year.
戴恩治疗公司(纳斯达克:DYN-GET评级)最近一次公布收益结果是在8月4日星期四。该公司公布本季度每股收益(1.01美元),低于(0.79美元)和(0.22美元)的普遍预期。卖方分析师平均预测,戴恩治疗公司本年度的每股收益将达到3.59美元。
About Dyne Therapeutics
戴恩治疗公司简介
(Get Rating)
(获取评级)
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
戴恩治疗公司是一家肌肉疾病公司,作为一家生物技术公司,专注于在美国推进遗传驱动的肌肉疾病的治疗。它利用其提供疾病修正疗法的FORCE平台,为强直性肌营养不良1型、Duchenne肌营养不良和面肩肩关节营养不良以及罕见的骨骼肌、心脏和代谢性肌肉疾病开发各种计划。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Dyne Therapeutics (DYN)
- 3 High Margin Chipmakers Bound to Recover
- 3 Solar Stocks That Will Benefit From the Biden Tariff Holiday
- REV Group Has A Deep Moat In The World Of EVs
- Is G-III Apparel Group, Ltd. A Value Trap?
- Bank Of America Sees Upside In These 2 European Alcohol Stocks
- 免费获取StockNews.com关于戴恩治疗公司(Dyn)的研究报告
- 3家高利润率芯片制造商势必复苏
- 将受益于拜登关税假期的3只太阳能股
- REV集团在电动汽车世界拥有深厚的护城河
- G-III服装集团有限公司是价值陷阱吗?
- 美国银行看好这两只欧洲酒类股票
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《戴恩治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收对戴恩治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧